Current inventions target new molecules that bind to B7-H3, which can be added to human B7-H3 and non-human B7-H3.In particular, this molecule is a B7-H3 cross-reactant with non-human primates.A month ago The invention also belongs to B7-H3 binding molecules, including variable light chain domains and/or variable heavy chain domains (VH), which have been humanized and/or dehumanized, reducing the immunity of receptors in management. This invention belongs in particular to bimolecule.Combining three or more characteristics of B7-H3,Including binary bodies,Bit...Pisces antibodyTrivalent binding moleculeThese include: (1) such a variable domain connected to B7-H3 and (2) a domain capable of combining a molecular entry on the surface of a radio battery. Another goal of the invention is to develop pharmaceutical compounds containing any such B7-H3 binding molecule.As well as involving the use of any such molecule binding to B7-H3 in the treatment of cancer and other diseases and diseases. The invention also belongs in particular to a molecule, which includes the B7-H3 binding domain of a human conjugate (B7-H3-ADC) consisting of at least part of an anti-human B7-H3 antibody. The invention is also directed at pharmaceutical compounds containing B7-H3-ADCS.And any method involving the use of B7-H3-ADC in the treatment of cancer and other diseases and diseases.La presente invención se dirige a moléculas de unión a B7-H3 novedosas capaces de unirse a B7-H3 humanas y no-humanas, y en particular a tales moléculas que son un reactivo cruzado con B7-H3 de un primate no humano (por ejemplo, un mono cynomolgus). La invención adicionalmente pertenece a las moléculas de unión a B7-H3 que comprenden Dominios de Cadena Ligera Variable y/o Cadena Pesada Variable (VH) que se han humanizado y/o deshumanizado de manera que presentan una inmunogenicidad reducida en la administración a los sujetos receptores. La invención particularmente pertenece a moléculas biespecíficas, triespecíficas o
